Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

  • Age-Related Macular Degeneration
Trial Status:

This trial runs in
Cities
  • 'Aiea
  • Abilene
  • Albacete
  • Albany
  • Albury
  • Ankara
  • Ann Arbor
  • Arlington
  • Asheville
  • Ashland
  • Augusta
  • Aurora
  • Austin
  • Bakersfield
  • Baltimore
  • Barcelona
  • Belfast
  • Bellevue
  • Bern
  • Beverly Hills
  • Bilbao
  • Binningen
  • Birmingham
  • Bloomfield
  • Boisbriand
  • Bonn
  • Bordeaux
  • Boston
  • Box Hill
  • Boynton Beach
  • Bradford
  • Bratislavský kraj
  • Bristol
  • Bruxelles
  • Budapest
  • Bydgoszcz
  • Bytom
  • Cardiff
  • Charlotte
  • Charlottesville
  • Chattanooga
  • Cherry Hill
  • Chesterfield
  • Chevy Chase
  • Cincinnati
  • Cleveland
  • Coimbra
  • Colorado Springs
  • Columbus
  • Créteil
  • Dallas
  • Debrecem
  • Detroit
  • Durham
  • East Melbourne
  • Edina
  • Edison
  • Florence
  • Fort Lauderdale
  • Fort Myers
  • Freiburg
  • Fullerton
  • Gdańsk
  • Genova
  • Germantown
  • Glostrup
  • Gloucestershire
  • Golden
  • Grand Rapids
  • Hannover
  • Hauppauge
  • Heidelberg
  • Henderson
  • Houston
  • Indianapolis
  • Katowice
  • Kraków
  • Köln
  • L'Hospitalet de Llobregat
  • La Jolla
  • Ladson
  • Las Vegas
  • Lawrenceville
  • Leiden
  • Leuven
  • Lexington
  • Lima
  • Linz
  • Lisboa
  • Liverpool
  • Los Angeles
  • Ludwigshafen
  • Lynbrook
  • Lyon
  • Lübeck
  • Madison
  • Madrid
  • Manchester
  • Marietta
  • Marseille
  • McAllen
  • Melbourne
  • Milano
  • Monroeville
  • Morgantown
  • Mountain View
  • München
  • Münster
  • Nantes
  • Naples
  • Nashville
  • New London
  • New York
  • Newcastle upon Tyne
  • Northfield
  • Oakland
  • Paducah
  • Palm Beach Gardens
  • Palm Desert
  • Palo Alto
  • Pamplona
  • Paris
  • Parramatta
  • Pensacola
  • Phoenix
  • Plantation
  • Portland
  • Poway
  • Pécs
  • Rapid City
  • Regensburg
  • Reno
  • Richmond
  • Rochester
  • Roma
  • Roskilde
  • Royal Oak
  • Sacramento
  • Saint Petersburg
  • Salt Lake City
  • San Francisco
  • Santa Ana
  • Santa Barbara
  • Santiago de Compostela
  • Shawnee Mission
  • Silverdale
  • Southampton
  • Southfield
  • Spokane
  • Sydney
  • Syracuse
  • Tallahassee
  • Tampa
  • Teaneck
  • Temple
  • The Woodlands
  • Torino
  • Towson
  • Trencin
  • Tucson
  • Tübingen
  • Udine
  • Valladolid
  • València
  • Walnut Creek
  • Warrenton
  • West Des Moines
  • West Mifflin
  • Westmead
  • Wichita
  • Wien
  • Willow Park
  • Winston-Salem
  • Wolverhampton
  • Worcester
  • Wrocław
  • York
  • Zilina
  • Zürich
  • Łódź
Trial Identifier:

NCT02745119 2016-000423-13 GX30191

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who received investigational lampalizumab, as well as lampalizumab-naive participants exposed to sham comparator. All participants will receive open-label lampalizumab in the present study.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02745119 , GX30191 , 2016-000423-13 Trial Identifier
      Lampalizumab Treatments
      Geographic Atrophy Condition
      Official Title

      A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study

      Eligibility Criteria

      All Gender
      No Healthy Volunteers
      Inclusion Criteria
      • Previous enrollment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531) with completion of treatment and the Week 96 visit
      • Agreement to remain abstinent or use a reliable form of contraception among all men and among women of child-bearing potential
      Exclusion Criteria
      • Concurrent ocular conditions that contraindicate use of lampalizumab or might affect interpretation of study results or that might increase the risk of treatment complications
      • Concurrent disease, metabolic dysfunction, or physical or laboratory finding that contraindicates use of lampalizumab or might affect interpretation of study results or that might increase the risk of treatment complications
      • Increased risk of infection
      • Pregnancy or lactation

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now